Sherwin-Williams High-Performance Flooring announced the launch of Accelera One, a grout and topcoat technology for pharmaceutical manufacturing environments. The technology offers benefits for pharmaceutical, life sciences, R&D and biopharma manufacturing spaces. A next-generation, ultra-high solids coating formulated to minimize downtime, it can also enhance durability and support green building goals. Accelera One delivers rapid cure…
Purdue, Eli Lilly, Merck form new pharma manufacturing consortium
Purdue University, Eli Lilly and Co., and Merck & Co. have launched the Young Institute Pharmaceutical Manufacturing Consortium, a collaborative effort to pioneer advances in making medicines. Operating within Purdue’s William D. and Sherry L. Young Institute for Advanced Manufacturing of Pharmaceuticals, consortium partners will focus on advancing pharmaceutical manufacturing, according to a Jan. 17 news…
CellProthera inks deal for GMP cell therapy manufacturing
CellProthera announced a deal with Shonan Kamakura General Hospital (SKGH) to transfer technology to enable cell therapy manufacturing for clinical trials. The memorandum of understanding allows for GMP manufacturing of CD34+ endothelial progenitor cells (EPCs) for autologous therapy clinical trials. Takayuki Asahara of SKGH intends to adopt CellProthera’s StemXpand platform for clinical trials starting next…
Eli Lilly to invest $3B in Wisconsin manufacturing plant expansion
Eli Lilly (NYSE:LLY) announced that it plans to invest $3 billion in the expansion of its manufacturing facility in Kenosha County, Wisconsin. In April, Indianapolis-based Eli Lilly acquired the plant in Pleasant Prairie, Wisconsin, from sterile manufacturer Nexus. The company expects its investment to extend its global parenteral (injectable) product manufacturing network. It aims to…
GBI Biomanufacturing expands capabilities with automated aseptic fill-finish
GBI Biomanufacturing announced today that it expanded its drug product (DP) services to include automated sterile fill and finish capabilities. Plantation, Florida–based GBI says it can support clients from clinical trials to commercial launch, both for drug products and drug substances. All of this can take place at its Florida plant, delivering advanced and flexible…
How biometric ID is boosting security and efficiency in pharma manufacturing
A maker of pharma manufacturing workstations says wearable biometric ID products are solving a security and efficiency challenge. Traditionally, pharmaceutical manufacturers have used a complex patchwork of access points, workstations, and tools, according to Fremont, California–based Arista Corp. Think badges, passwords and more, with the potential for someone other than the intended operator to gain…
Cellular Origins, Fresenius Kabi partner to automate cell, gene therapy manufacturing
Cellular Origins and Fresenius Kabi announced today that they signed a development agreement over cell and gene therapies (CGTs). The agreement leverages both companies’ expertise in CGTs. They aim to digitally and physically integrate Fresenius Kabi’s suite of cell therapy processing technologies with Cellular Origins’ CGT robotic manufacturing platform, Constellation. With this integration, the companies…
Nipro launches new glass vials powered by Stevanato Group’s EZ-fill tech
Nipro PharmaPackaging announced today that it launched new D2F (direct-to-fill) glass vials powered by Stevanato Group technology. The vials feature Stevanato’s EZ-fill technology to offer a high-quality, ready-to-use (RTU) solution. Nipro designed the vials to meet the rigorous standards and increasing requirements of the pharmaceutical industry. D2F vials are washed, depyrogenated, packaged in nest and…
PCI Pharma Services makes $365M investment in drug delivery device manufacturing
PCI Pharma Services announced that it’s investing more than $365 million in infrastructure to support assembly and packaging efforts. The investment supports the clinical- and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. PCI Pharma plans to put its investment toward new and…
Wheeler Bio licenses antibody production tech from ATUM
Wheeler Bio announced today that it expanded its capabilities through the licensing of ATUM’s miFuc platform. ATUM designed miFuc for the expression of recombinant proteins containing afucosylated glycans. The technology supports the development of antibodies with a significant reduction in fucosylation without affecting product titer, cellular growth rates or incurring global glycan liabilities. ATUM’s proprietary…